Capital International Inc. CA Purchases 97,550 Shares of Boston Scientific Co. (NYSE:BSX)

Capital International Inc. CA increased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 193.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 148,059 shares of the medical equipment provider's stock after acquiring an additional 97,550 shares during the period. Capital International Inc. CA's holdings in Boston Scientific were worth $13,225,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Parnassus Investments LLC boosted its stake in shares of Boston Scientific by 0.7% during the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock valued at $1,327,000 after purchasing an additional 97 shares during the period. Evergreen Capital Management LLC raised its stake in shares of Boston Scientific by 1.7% in the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after purchasing an additional 106 shares during the last quarter. PDS Planning Inc boosted its holdings in Boston Scientific by 1.5% in the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after purchasing an additional 113 shares during the last quarter. Adero Partners LLC increased its position in shares of Boston Scientific by 3.3% during the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock valued at $334,000 after purchasing an additional 120 shares during the last quarter. Finally, Grove Bank & Trust raised its holdings in Boston Scientific by 4.4% in the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock worth $261,000 after purchasing an additional 122 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Citigroup lifted their target price on Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Needham & Company LLC raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $113.00 price objective on the stock in a report on Wednesday, April 16th. Truist Financial dropped their target price on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Royal Bank of Canada raised their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, BTIG Research reissued a "buy" rating on shares of Boston Scientific in a report on Wednesday. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $110.22.

Insider Activity at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the sale, the chief financial officer now directly owns 225,808 shares of the company's stock, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 138,009 shares of company stock valued at $14,407,381 in the last 90 days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 4.2 %

Shares of BSX stock traded up $3.96 during trading hours on Wednesday, hitting $99.01. 12,865,196 shares of the company were exchanged, compared to its average volume of 6,403,154. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $146.44 billion, a PE ratio of 79.21, a PEG ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a 52 week low of $70.97 and a 52 week high of $107.17. The business has a 50 day moving average of $99.00 and a two-hundred day moving average of $94.55.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.